Jinxiang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinxiang Yang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jianying Liang
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 shared publications - Bing Wang
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications Guofang Li
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publicationsXiaobo Feng
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publicationsZhen Zhang
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publicationsZhiRong Yao
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 9 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108776
Virus-associated immune dysregulation presenting as facial granulomatous dermatitis in DiGeorge syndrome: A case series
- 9 May 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 169, 108776
Open AccessVirus-associated immune dysregulation presenting as facial granulomatous dermatitis in DiGeorge syndrome: A case series
- 10 April 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (4) , e70097
Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome
Severe dermatitis, multiple allergies, and metabolic wasting syndrome (SAM) is a rare inherited disorder caused by biallelic loss‐of‐function mutations in the desmoglein‐1 (DSG1) or desmoplakin (DSP) genes. Previous studies have demonstrated that acitretin and systemic biologics targeting IL‐17, IL‐12/IL‐23, and IL‐4 are effective in treating SAM syndrome. We report the case of an 8‐year‐old girl diagnosed with SAM syndrome who suffered from recurrent rash episodes due to infections and achieved remission with a combination therapy of Spesolimab and acitretin. Comprehensive diagnostic workup, including serum inflammatory factor assays, flow cytometry, skin immunohistochemical staining, and skin RNA sequencing (RNA‐seq), revealed elevated IL‐36G levels in SAM syndrome, which may be associated with the pathogenesis of generalised pustular psoriasis (GPP) through shared IL‐36‐mediated mechanisms. This case highlights the therapeutic potential of targeting the IL‐36 pathway in SAM syndrome and supports the use of skin RNA‐seq for personalised selection of anti‐inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach.
- 10 April 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (4) , e70097
Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome
Severe dermatitis, multiple allergies, and metabolic wasting syndrome (SAM) is a rare inherited disorder caused by biallelic loss‐of‐function mutations in the desmoglein‐1 (DSG1) or desmoplakin (DSP) genes. Previous studies have demonstrated that acitretin and systemic biologics targeting IL‐17, IL‐12/IL‐23, and IL‐4 are effective in treating SAM syndrome. We report the case of an 8‐year‐old girl diagnosed with SAM syndrome who suffered from recurrent rash episodes due to infections and achieved remission with a combination therapy of Spesolimab and acitretin. Comprehensive diagnostic workup, including serum inflammatory factor assays, flow cytometry, skin immunohistochemical staining, and skin RNA sequencing (RNA‐seq), revealed elevated IL‐36G levels in SAM syndrome, which may be associated with the pathogenesis of generalised pustular psoriasis (GPP) through shared IL‐36‐mediated mechanisms. This case highlights the therapeutic potential of targeting the IL‐36 pathway in SAM syndrome and supports the use of skin RNA‐seq for personalised selection of anti‐inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach.
- 14 March 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (3)
Similar Molecular Features in Two Cases of CARD14‐Associated Papulosquamous Eruption
Subjects carrying variants in the caspase recruitment domain family member 14 (CARD14) gene can exhibit characteristics of psoriasis and pityriasis rubra pilaris (PRP). The term ‘CARD14‐associated papulosquamous eruption (CAPE)’ is used to describe individuals presenting with symptoms of both conditions. This study aimed to diagnose two cases of CAPE and explore the pathogenic mechanisms, including inflammatory trends and differential features. Whole‐exome sequencing and Sanger sequencing identified a novel variant, c.2768T>C and a recurrent variant, c.467T>C, in CARD14 in two unrelated individuals, both exhibiting incomplete penetrance. Both of patients exhibited increased IL‐17A in skin lesions, but not in serum, potentially explaining the reported cases with low response rate to secukinumab. One patient also exhibited increased IL‐23A in serum. Additionally, the epidermis of lesions showed aberrant late differentiation and active NF‐κB signalling.
- 14 March 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (3)
Similar Molecular Features in Two Cases of CARD14‐Associated Papulosquamous Eruption
Subjects carrying variants in the caspase recruitment domain family member 14 (CARD14) gene can exhibit characteristics of psoriasis and pityriasis rubra pilaris (PRP). The term ‘CARD14‐associated papulosquamous eruption (CAPE)’ is used to describe individuals presenting with symptoms of both conditions. This study aimed to diagnose two cases of CAPE and explore the pathogenic mechanisms, including inflammatory trends and differential features. Whole‐exome sequencing and Sanger sequencing identified a novel variant, c.2768T>C and a recurrent variant, c.467T>C, in CARD14 in two unrelated individuals, both exhibiting incomplete penetrance. Both of patients exhibited increased IL‐17A in skin lesions, but not in serum, potentially explaining the reported cases with low response rate to secukinumab. One patient also exhibited increased IL‐23A in serum. Additionally, the epidermis of lesions showed aberrant late differentiation and active NF‐κB signalling.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 427-430
Successful Treatment of Facial Multiple Melanocytic Nevus-Like Dark Macules Caused by Severe Acne Vulgaris by a Single Session of Intense Pulsed Light Treatment
Background and Objective: The case report aims to demonstrate the therapeutic effects of a single session of intense pulsed light (IPL) treatment on facial multiple melanocytic nevus-like dark macules induced by severe acne vulgaris. Materials and Methods: A 17-year-old male with acne was assessed as Pillsbury IV according to the Pillsbury classification. After three sessions of photodynamic therapy (PDT), he experienced an increase in number and darkening of facial melanocytic nevus-like dark macules. We attempted to use broadband light (BBL) (SCITON Company, USA) (420nm, 8J, 180ms; 515nm, 13J, 20ms; 560nm, 16J, 24ms; 590nm, 16J, 24ms) therapy to improve post-inflammatory erythema (PIE) and post-inflammatory hyperpigmentation (PIH). Following a baseline assessment, we performed a single session of IPL treatment on the patient and evaluated the changes in melanocytic nevus-like dark macules, PIE, PIH, and sebum secretion through standardized photography. Results: Compared to the baseline, we observed a significant reduction of the patient’s melanocytic nevus-like dark macules and a significant improvement in PIE, PIH, and sebum secretion after a single IPL treatment. Conclusions: This study provides preliminary evidence of the effects of IPL treatment on melanocytic nevi associated with severe acne vulgaris. Further research is warranted to elucidate the underlying mechanisms and promote the wider application of this treatment modality in managing acne sequelae.
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 427-430
Open AccessSuccessful Treatment of Facial Multiple Melanocytic Nevus-Like Dark Macules Caused by Severe Acne Vulgaris by a Single Session of Intense Pulsed Light Treatment
Background and Objective: The case report aims to demonstrate the therapeutic effects of a single session of intense pulsed light (IPL) treatment on facial multiple melanocytic nevus-like dark macules induced by severe acne vulgaris. Materials and Methods: A 17-year-old male with acne was assessed as Pillsbury IV according to the Pillsbury classification. After three sessions of photodynamic therapy (PDT), he experienced an increase in number and darkening of facial melanocytic nevus-like dark macules. We attempted to use broadband light (BBL) (SCITON Company, USA) (420nm, 8J, 180ms; 515nm, 13J, 20ms; 560nm, 16J, 24ms; 590nm, 16J, 24ms) therapy to improve post-inflammatory erythema (PIE) and post-inflammatory hyperpigmentation (PIH). Following a baseline assessment, we performed a single session of IPL treatment on the patient and evaluated the changes in melanocytic nevus-like dark macules, PIE, PIH, and sebum secretion through standardized photography. Results: Compared to the baseline, we observed a significant reduction of the patient’s melanocytic nevus-like dark macules and a significant improvement in PIE, PIH, and sebum secretion after a single IPL treatment. Conclusions: This study provides preliminary evidence of the effects of IPL treatment on melanocytic nevi associated with severe acne vulgaris. Further research is warranted to elucidate the underlying mechanisms and promote the wider application of this treatment modality in managing acne sequelae.